多黏菌素药敏试验:挑战、问题与建议
多黏菌素B和多黏菌素E(黏菌素)越来越多用于治疗多重耐药革兰阴性菌感染,但药敏试验面临多重困难。本文讨论影响现有药敏方法结果的问题,并提供关于多黏菌素耐药机制(包括染色体和质粒介导的mcr相关耐药)的新概念。
要点
- 多黏菌素药敏试验困难源于其多组分构成、琼脂扩散差、吸附于微孔板等因素。
- 缺乏可靠的药敏试验方法和专业机构特定的折点值是主要挑战。
- 需关注多黏菌素异质性耐药及mcr相关耐药机制。
核心结论
- 多黏菌素药敏试验存在多重困难,影响现有方法结果的准确性,需重视耐药机制研究以指导有效治疗。
研究设计与样本
- 本文为小型综述,讨论多黏菌素药敏试验的挑战、问题与建议,未报告系统检索范围。
主要发现
- 多黏菌素药敏试验困难的原因包括多组分构成、琼脂扩散差、吸附于微孔板、缺乏可靠药敏试验、缺乏专业机构特定折点、聚山梨酯80的协同效应及异质性耐药的发生。
- 多黏菌素耐药机制包括染色体介导和质粒介导的mcr相关耐药。
临床怎么用
- 实验室需采用准确可靠的方法进行多黏菌素常规药敏试验,并关注异质性耐药及mcr相关耐药机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polymyxins, including polymyxin B and polymyxin E (colistin), are now increasingly being used worldwide to treat patients with multidrug-resistant (MDR) Gram-negative bacterial infections. This necessitates that laboratories employ an accurate and reliable method for the routine performance of polymyxin susceptibility testing. A number of reasons have accounted for the difficulties with susceptibility testing for the polymyxins, including their multicomponent composition, poor diffusion in the agar medium, adsorption to microtiter plates, the lack of a reliable susceptibility test, the lack of a specific breakpoint from professional organizations, the synergistic effect of polysorbate 80, and the development of heteroresistance. This minireview discusses such problems that impact the results of currently available susceptibility testing methods. We also provide emerging concepts on mechanisms of polymyxin resistance, including chromosomally and plasmid-mediated mcr-related resistance. Broad-range investigations on such critical issues in relation to polymyxins can be beneficial for the implementation of effective treatment against MDR Gram-negative bacterial infections.
引用
- Ezadi F, Ardebili A, Mirnejad R, et al. Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations. J Clin Microbiol. 2019. PMID: 30541939. doi:10.1128/JCM.01390-18
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。